Table 7.
Parameter | Non-infected | Infected | ||||
---|---|---|---|---|---|---|
Control G1 | SMC G2 | Non-treated G3 | SMC low dose G4 | SMC high dose G5 | Diclazuril G6 | |
ALT (U/L) | 6.00 ± 1.41e | 5.66 ± 0.47a | 14.66 ± 1.24b | 5.00 ± 0.81c | 7.00 ± 0.81d | 5.33 ± 0.94d |
AST (U/L) | 213.67 ± 7.76e | 193.66 ± 7.36a | 284.33 ± 05.31b | 223.66 ± 3.39c | 229.33 ± 18.08d | 192 ± 12.83d |
ALP (U/L) | 1623.3 ± 107.28e | 1623 ± 128.83a | 2,277 ± 189.64b | 1,491 ± 91.17c | 1.353 ± 88.58d | 1424.33 ± 68.66d |
T P (g/dl) | 5.00 ± 0.81a | 5.33 ± 0.47e | 4.06 ± 0.16d | 5.00 ± 0.81c | 5.53 ± 0.41b | 4.73 ± 0.52b |
Albumin (g/dl) | 1.53 ± 0.17a | 1.83 ± 0.09e | 1.76 ± 0.20d | 1.93 ± 0.18c | 1.96 ± 0.19b | 1.76 ± 0.12b |
Creatinine (mg/dl) | 0.56 ± 0.04e | 0.53 ± 0.04a | 0.70 ± 0.08b | 0.56 ± 0.04c | 0.56 ± 0.04cde | 0.55 ± 0.05cde |
Uric acid (mg/dl) | 7.08 ± 1.93e | 6.08 ± 0.33a | 6.08 ± 0.33a | 6.18 ± 0.82c | 8.07 ± 1.14de | 8.07 ± 1.14de |
Means within rows with different superscripts differ at p ≤ 0.05. a, b, c, and d indicate statistical significance in comparison with control, infected non-treated, low dose SMC-treated, and diclazuril-treated groups, receptively. Means within rows with different superscripts differ at p ≤ 0.05.